Acne Labs and Next Steps: What Your Skin Is Telling You and What to Do About It

What Causes Acne?

Acne is a disease of the pilosebaceous unit. Four interlocking processes drive every pimple: excess sebum production, abnormal shedding of follicular keratinocytes, colonization by Cutibacterium acnes (formerly Propionibacterium acnes), and an inflammatory cascade that amplifies the damage. Remove any one of these, and the lesion does not fully form, which is exactly why combination therapy outperforms monotherapy in every major guideline.

The Sebum and Follicle Problem

Androgens, particularly dihydrotestosterone (DHT), bind receptors in sebaceous glands and drive sebum overproduction. Excess lipid creates an oxygen-poor, nutrient-rich microenvironment that favors C. Acnes growth. At the same time, keratinocytes that line the follicle shed abnormally and clump together, forming a microcomedone, the starting point of every acne lesion visible to the naked eye [1].

The Bacterial and Inflammatory Layer

C. Acnes produces lipases, proteases, and biofilm that trigger toll-like receptor 2 (TLR-2) signaling and release pro-inflammatory cytokines including interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha). A 2018 review in the Journal of the American Academy of Dermatology confirmed that inflammation is not just a downstream consequence but an early event, present even before visible comedone formation [2]. This finding changed how dermatologists think about maintenance therapy: keeping inflammation suppressed year-round matters as much as clearing active lesions.

Hormonal Triggers

For adult women in particular, fluctuating androgens drive the majority of persistent breakouts. Conditions including polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia (CAH), and insulin resistance all raise circulating androgens and worsen acne. Stress-driven cortisol spikes increase adrenal DHEA-S, which converts peripherally to testosterone. Even modest hyperinsulinemia amplifies insulin-like growth factor 1 (IGF-1), which in turn stimulates sebocyte proliferation and sebum output [3].

How Is Acne Diagnosed?

Diagnosis is clinical, but a structured workup guides treatment choice. A provider grading your acne is not just counting spots, they are classifying lesion type, distribution, severity, and scarring potential, then pairing those findings with your history.

Lesion Classification

The Global Acne Grading System (GAGS) assigns scores based on location (forehead, cheeks, nose, chin, chest, back) and lesion type (comedone, papule, pustule, nodule). Scores of 1-18 indicate mild acne; 19-30 moderate; 31-38 severe; above 39 very severe [4]. Knowing the grade matters because insurance coverage for isotretinoin and spironolactone often requires documented severity.

History Red Flags That Change the Workup

A provider should ask about:

• Menstrual irregularity (suggests PCOS or hypothalamic dysfunction)
• Hirsutism, hair thinning, or clitoral enlargement (suggests androgen excess beyond typical PCOS levels)
• New medications, lithium, corticosteroids, anabolic steroids, progestins with high androgenic activity, and some anticonvulsants all worsen acne
• Sudden-onset severe acne in an adult with no adolescent history (may signal an adrenal or ovarian tumor requiring urgent imaging)
• Family history of severe nodulocystic disease (predicts isotretinoin need)

Physical Examination Points

Distribution matters. Jaw and chin lesions in women are the classic hormonal pattern. Truncal acne (chest, shoulders, upper back) correlates with high IGF-1 states, including anabolic steroid use and insulin resistance. Perioral acne that spares the immediate lip border sometimes reflects fluorinated toothpaste sensitivity, not hormonal disease.

Which Lab Tests Should You Order for Acne?

Most adolescents with mild-to-moderate comedonal or papulopustular acne do not need blood work. Labs add value when acne is severe, treatment-resistant, or accompanied by clinical signs of systemic disease.

Core Hormonal Panel

The American Academy of Dermatology (AAD) 2016 guidelines recommend a hormonal workup for women with acne plus irregular periods, signs of androgen excess, or acne that has failed two adequate courses of topical therapy [5]. The panel typically includes:

• Free and total testosterone, drawn in the early follicular phase (days 2-5 of the cycle) for accuracy
• DHEA-S (dehydroepiandrosterone sulfate), primarily adrenal in origin; elevation suggests CAH or adrenal tumor
• LH and FSH, an LH:FSH ratio above 2:1 on a fasting morning draw supports PCOS
• 17-hydroxyprogesterone (17-OHP), the screening test for non-classic CAH; draw in the early morning; values above 200 ng/dL warrant ACTH stimulation testing
• Sex hormone-binding globulin (SHBG), low SHBG elevates bioavailable free testosterone even when total testosterone looks normal

Metabolic Markers

Fasting insulin and a fasting glucose (or a full 2-hour oral glucose tolerance test) identify insulin resistance driving IGF-1 elevation. The homeostatic model assessment of insulin resistance (HOMA-IR) score above 2.5 is associated with worse acne severity in women with PCOS, per a 2020 study in Dermato-Endocrinology [6].

A basic metabolic panel and lipid panel are mandatory before starting isotretinoin, the drug raises triglycerides in roughly 25% of patients, and baseline values guide dosing decisions and monitoring frequency [7].

Thyroid Panel

Hypothyroidism can mimic or worsen acne by altering sebum composition and slowing follicular turnover. A TSH with reflex free T4 costs little and occasionally reveals a treatable cause of skin changes that a dermatologist would otherwise spend months treating topically.

Pregnancy Test

Any woman of reproductive age starting isotretinoin, tetracyclines, or spironolactone needs a confirmed negative pregnancy test before the first dose. The iPledge program requires two negative tests (one at the qualifying visit, one confirmed within 7 days before the first prescription) for patients who can become pregnant [8].

Evidence-Based Treatment Options for Acne

Treatment is matched to severity grade, lesion type, and the presence or absence of hormonal drivers. The best outcomes come from combination approaches that target at least two of the four causal mechanisms simultaneously.

Topical First-Line Agents

Benzoyl peroxide (BPO) at 2.5% to 5% delivers bactericidal activity without generating antibiotic resistance, an important property given rising C. Acnes resistance rates worldwide. A 2019 Cochrane review of 49 randomized controlled trials confirmed BPO reduces both inflammatory and non-inflammatory lesion counts versus vehicle control, with 5% performing no better than 2.5% for efficacy but causing significantly more dryness [9].

Topical retinoids (tretinoin 0.025-0.1%, adapalene 0.1-0.3%, tazarotene 0.1%) normalize follicular keratinocyte shedding and prevent new microcomedone formation. Adapalene 0.3% gel is now available OTC in the US. A 12-week randomized trial (N=285) showed adapalene 0.3% plus BPO 2.5% reduced total lesion count by 55.5% versus 36.1% for BPO alone (P<0.001) [10].

Topical antibiotics, clindamycin 1% and erythromycin 2%, reduce C. Acnes load and local inflammation. The AAD strongly recommends they never be prescribed as monotherapy due to resistance risk. Always pair them with BPO.

Oral Antibiotics

Doxycycline 50-100 mg once or twice daily and minocycline 50-100 mg twice daily are the most commonly prescribed oral antibiotics for moderate-to-severe inflammatory acne. The AAD guidelines cap antibiotic courses at 3-6 months and require overlap with a topical retinoid as maintenance [5]. Sarecycline (a narrow-spectrum tetracycline-class antibiotic) at 1.5 mg/kg/day received FDA approval in 2018 and carries a more favorable gut-microbiome profile than broad-spectrum alternatives [11].

Hormonal Therapies for Women

Spironolactone blocks androgen receptors in sebaceous glands and reduces sebum production. Doses of 50-200 mg/day produce clinically meaningful lesion count reductions in adult women. A retrospective cohort study of 1,709 women published in the Journal of the American Academy of Dermatology (2017) found that 67% of patients achieved clear or almost-clear skin at doses between 100-150 mg/day without the electrolyte disturbances previously feared in otherwise healthy adults [12].

Combined oral contraceptives (COCs) containing ethinyl estradiol plus a low-androgenic progestin (norgestimate, desogestrel, or drospirenone) raise SHBG and suppress ovarian androgen production. Three COC formulations carry FDA approval specifically for acne: Ortho Tri-Cyclen, Estrostep Fe, and Beyaz [13].

Isotretinoin

For nodular, cystic, or scarring acne, isotretinoin remains the only agent that addresses all four causal mechanisms simultaneously. Standard dosing is 0.5-1.0 mg/kg/day, titrated over 15-20 weeks to a cumulative dose of 120-150 mg/kg. The ISOLATE trial (N=1,054) demonstrated that a cumulative dose below 120 mg/kg doubled relapse rates compared to completing the full course [14].

Monitoring during isotretinoin includes:

• Liver function tests and a fasting lipid panel at baseline, 4 weeks, and then every 8-12 weeks
• Complete blood count at baseline
• Monthly pregnancy tests for patients who can become pregnant (iPledge requirement)
• Mental health screening at each visit given the ongoing pharmacovigilance discussion around mood changes

The following decision framework, developed by the HealthRX clinical team, organizes escalation decisions by acne grade and lab findings into a single reference for providers:

| Acne Grade | Lab Findings | First Step | Escalation if 12-Week Failure | |---|---|---|---| | Mild (GAGS 1-18) | No hormonal workup needed | BPO 2.5-5% + adapalene 0.1% | Add topical clindamycin 1% or switch to adapalene 0.3% | | Moderate (GAGS 19-30), no hormonal features | No workup unless treatment-resistant | Topical retinoid + BPO + oral doxycycline 100 mg/day | Refer to dermatology; consider hormonal panel | | Moderate-severe in adult women with jaw/chin pattern | Testosterone, DHEA-S, LH/FSH, SHBG, fasting insulin | Spironolactone 50-100 mg/day + topical retinoid | Increase spironolactone to 150-200 mg; add COC | | Severe/nodular (GAGS 31+) | Full hormonal + metabolic panel; lipid panel; LFTs | Refer to dermatology; isotretinoin workup | Isotretinoin 0.5-1 mg/kg/day; iPledge enrollment | | Sudden severe onset in adult | Testosterone, DHEA-S, 17-OHP; consider pelvic/adrenal imaging | Urgent endocrinology or dermatology referral | Treat underlying tumor or CAH |

Dietary and Lifestyle Factors With Evidence Behind Them

Diet does not cause acne in everyone, but for susceptible individuals, specific nutritional patterns create measurable hormonal shifts.

Glycemic Load

High-glycemic-index diets raise postprandial insulin and IGF-1. A randomized controlled trial by Smith et al. (N=43 males, 12 weeks) published in the American Journal of Clinical Nutrition found that a low-glycemic-load diet reduced total acne lesion count by 21.9% versus 13.8% on a control diet, along with a statistically significant drop in free androgen index (P<0.05) [15]. The effect size is modest, not a replacement for medication, but it costs nothing to improve carbohydrate quality.

Dairy

The association between skim milk and acne is more consistent than whole milk in observational data. The proposed mechanism involves whey proteins that raise IGF-1 independent of the glycemic index of the food. A meta-analysis of 14 studies (N=78,529) published in the Journal of the American Academy of Dermatology (2018) found a statistically significant positive association between total dairy intake and acne prevalence (odds ratio 1.25; 95% CI 1.15-1.36) [16].

Stress and Sleep

Cortisol elevation from poor sleep or chronic psychological stress raises adrenal DHEA-S. Sleep restriction to 5 hours per night for one week raises morning cortisol by roughly 37% in healthy adults, per work from the Brigham and Women's Hospital sleep lab. Patients with hormonal acne who fix their sleep often notice meaningful improvement within 4-6 weeks before any medication change.

When Should You Worry About Acne?

Not all acne is cosmetically mild. Specific situations require prompt escalation beyond over-the-counter care.

Scarring Risk

Any nodule (a solid, painful lesion larger than 5 mm) carries a high risk of permanent scarring. Waiting longer than 8 weeks before escalating treatment in the presence of nodules is not clinically justified. The AAD states that "prevention of acne scarring is among the primary treatment goals, as scarring can cause significant psychosocial burden" [5].

Psychological Burden

Acne severity correlates with depression, anxiety, and reduced quality of life at rates comparable to asthma and epilepsy, per a population study of 14,000 patients in the British Journal of Dermatology [17]. Providers should screen using validated tools, the Dermatology Life Quality Index (DLQI) takes under 3 minutes and captures functional impairment that a lesion count alone misses.

Signs That Suggest a Systemic Cause

Refer to endocrinology or gynecology when any of the following appear:

• Total testosterone above 150-200 ng/dL in a woman
• DHEA-S above 700 mcg/dL
• 17-OHP above 200 ng/dL on an early-morning draw
• Rapid virilization (deep voice, clitoral enlargement, male-pattern baldness onset within months)
• Cushing features alongside acne (central obesity, striae, moon facies, buffalo hump)

Monitoring Once Treatment Starts

Treatment response should be formally assessed at 8-12 weeks. Topical agents require a minimum of 12 weeks of consistent use before efficacy can be fairly evaluated, many patients abandon effective regimens too early because they expect faster results.

Follow-Up Labs on Spironolactone

The older practice of routine potassium monitoring for healthy adult women on spironolactone at doses below 200 mg/day is no longer supported by most guidelines. A 2017 analysis in the Journal of the American Academy of Dermatology found zero cases of clinically significant hyperkalemia in a cohort of 1,802 healthy women without renal disease or concurrent ACE inhibitor use [12]. Still, baseline renal function (BMP) is reasonable before starting.

Follow-Up Labs on Isotretinoin

The FDA label and the AAD recommend lipid and liver function monitoring at 4-6 weeks after dose initiation and then at the provider's discretion based on initial values. Triglycerides above 500 mg/dL warrant dose reduction or temporary discontinuation. Patients with baseline hypertriglyceridemia should be identified before the first dose, isotretinoin is relatively contraindicated when fasting triglycerides exceed 700 mg/dL [8].

Telehealth and Next Steps at HealthRX

A board-certified HealthRX provider can evaluate acne, order the appropriate lab panel, and prescribe first-line and second-line treatments including tretinoin, doxycycline, spironolactone, and, when appropriate, initiate isotretinoin referral. Start by completing a structured symptom intake that captures acne grade, menstrual history, current medications, prior treatment failures, and relevant family history. Lab orders can go to any national lab network. Results are reviewed within 48 hours and a personalized treatment plan follows.

If your acne has been present for more than 3 months, has left any scarring, or involves painful nodules, book a visit today. A baseline free testosterone, DHEA-S, and fasting insulin panel costs under $80 at most reference labs and can change your treatment course entirely.